Month: March 2025

The share repurchase programme runs as from 26 February 2025 and up to and including 30 January 2026 at the latest. In this period, Jyske Bank will acquire shares with a value of up to DKK 2.25 billion, cf. Corporate Announcement No. 3/2025 of 26 February 2025. The share repurchase programme is initiated and structured in compliance with the EU Commission Regulation No. 596/2014 of 16 April 2014, the so-called “Market Abuse Regulation”, and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (together with the Market Abuse Regulation, the “Safe Harbour Rules”). The following transactions have been made under the program:  Number of shares Average purchase price (DKK) Transaction value (DKK)Accumulated, previous announcement 71,716 581.53 41,705,31024 March 2025 3,909 587.82 2,297,80225 March...

Schiltigheim, March 31th 2025 08:00, Tonner Drones (’the Company’) is pleased to announce that it was able to agree on a final amendment to the settlement contract with former management to hold its original number of 11,4% Elistair shares. In September 2024 Tonner Drones and former management decided to split ways. At that moment, the cash position of the company was low, and it was decided to sell 50% of its stake in Elistair to Ott Heritage and Bradley Taylor in exchange for €800.000 in receivables they had against the company. Today, Tonner Drones has a strong cash position and, in the meantime, the transfer of shares of Elistair was not yet finalized. This opened up an opportunity to unwind the transaction. Tonner drones will pay €471,463 and will keep its original stake of 11,4% of the shares in French Drone-company Elistair. With...

Saint Herblain (France), March 31, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that it has submitted a label extension application to the Medicines and Healthcare products Regulatory Agency (MHRA) of the United Kingdom (UK) to potentially expand the use of its chikungunya vaccine, IXCHIQ®, currently approved in adults1, to adolescents aged 12 to 17 years in the UK. This submission follows the recent positive opinion of the European Medicines Agency (EMA) on extension of IXCHIQ® label to adolescents in the European Union (EU)2. IXCHIQ® is the world’s first licensed chikungunya vaccine available to address this significant unmet medical need. It is approved in the U.S.3, Europe4, Canada5 and the UK for the prevention of disease caused by the chikungunya virus in individuals 18 years...

After nearly seven years as a member of the Executive Committee of Novartis (ECN), Klaus Moosmayer will pursue his next chapter of leadership outside of NovartisKaren Hale to drive the next phase of enterprise alignment for our Legal and ERC functionsBasel, March 31, 2025 – Novartis announced today the appointment of Karen Hale to the expanded role of Chief Legal and Compliance Officer for Novartis, effective April 14, 2025. She will continue to report to Vas Narasimhan, M.D., CEO of Novartis and remain on the Executive Committee of Novartis (ECN). Klaus Moosmayer, currently Chief Ethics, Risk & Compliance Officer of Novartis, has decided to leave the company and will step down from the ECN to pursue his next chapter of leadership outside Novartis. The current Ethics Risk & Compliance (ERC) function will move under the...

Company announcement no. 16 / 2025Schindellegi, Switzerland – 31 March 2025 Trifork Group: Weekly report on share buyback On 28 Februay 2025, Trifork initiated a share buyback program in accordance with Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and Commission Delegated Regulation (EU) 2016/1052, (Safe Harbour regulation). The share buyback program runs from 4 March 2025 up to and including no later than 30 June 2025. The buyback program will not be active from 9 to 15 April 2025. For details, please see company announcement no. 7 of 28 February 2025. Under the share buyback program, Trifork will purchase shares for up to a total of DKK 14.92 million (approximately EUR 2 million). Prior to the launch of the share buyback, Trifork held 256,329 treasury shares, corresponding to 1.3% of the share...

ShORe Phase 3 topline results accelerated; trial did not meet primary endpoint of mean change in BCVA from baseline to week 52 Opthea and DFA Investors agreed to terminate both COAST and ShORe trials Opthea continues to consider impact of negative trial results under its Development Funding Agreement (DFA) and on the Company as a going concern MELBOURNE, Australia and PRINCETON, N.J., March 31, 2025 (GLOBE NEWSWIRE) — Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced updates on its Phase 3 clinical program, including the termination of COAST (Combination of OPT-302 with Aflibercept Study) and accelerated topline results...

Mt. Olive, NJ, March 30, 2025 (GLOBE NEWSWIRE) — Vislink Technologies, Inc. (“Vislink” or the “Company”) (OTCQB: VISL), a global technology leader in the capture, delivery, and management of high-quality live video and associated data in the media and entertainment, law enforcement, and defense markets, announces that its fourth quarter and full year 2024 earnings release and related conference call are being delayed because the company requires additional time to finalize its consolidated audited financial statements for the year ended December 31, 2024. The company anticipates that it will issue the earnings release, hold the related conference call, and file its Annual Report on Form 10-K as soon as possible, but no later than April 15, 2025, as permitted by the applicable rules of the Securities and Exchange Commission.  Note...

  Press Release  2degrees and Nokia accelerate delivery of 5G services and improve network efficiency in New Zealand2degrees and Nokia sign six-year deal to utilize Nokia’s containerized Cloud Native Communication Suite (CNCS).CNCS, through the Nokia Cloud Platform, will streamline network activities, enhance automation, and minimize manual intervention across 2degrees’ network.CNCS will be deployed on the Nokia Cloud Platform, which integrates a full set of Red Hat cloud products, including Red Hat OpenShift.31 March 2025 Espoo, Finland – 2degrees is expanding its Voice Core relationship with Nokia in a six-year deal in which the New Zealand operator will tap Nokia’s containerized Cloud Native Communication Suite (CNCS) to accelerate the deployment of new 5G services and optimize its network resources. CNCS makes it easier...

HOUSTON, March 30, 2025 (GLOBE NEWSWIRE) — Amplify Energy Corp. (NYSE: AMPY) (“Amplify,” the “Company,” “us,” or “our”) has mandated Arctic Securities AS and DNB Markets, a part of DNB Bank ASA, as joint bookrunners to arrange a series of fixed income investor meetings commencing March 31, 2025. A new USD-denominated, 5-year senior unsecured bond issue (the “Bonds”) may follow, subject to market conditions, among other factors (the “Contemplated Bond Offering”). The net proceeds from the Contemplated Bond Offering is expected to be applied towards partial repayment of the Company’s reserve-based lending facility and general corporate purposes. The Bonds, if issued, will be offered and sold in the United States or its territories only to persons reasonably believed to be qualified institutional buyers in reliance on Rule 144A under...